NorthStar, IBA expand Tc-99m collaboration

2019 09 21 00 44 1021 Iba Astro 2019

NorthStar Medical Radioisotopes and proton therapy developer Ion Beam Applications (IBA) are expanding their collaboration in an effort to increase the supply of technetium-99m (Tc-99m) around the world.

Under the new partnership, companies outside the U.S. will now be able to purchase Tc-99m generation systems that utilize NorthStar's nonuranium-based molybdenum-99 (Mo-99) produced using IBA's accelerators and beamlines, according to the vendors. Mo-99 is the precursor to Tc-99m.

The expanded partnership builds on a previous contract under which IBA is providing NorthStar with up to eight of its Rhodotron TT 300-HE electron beam accelerators for producing nonuranium-based Mo-99. NorthStar's RadioGenix system will then use the Mo-99 to produce Tc-99m in the U.S.

The first pair of IBA accelerators are expected to arrive from Belgium in early April at NorthStar's expanded accelerator production facility in Beloit, WI.

Page 1 of 549
Next Page